New study aims to unlock secrets of CMV in transplant patients
NCT ID NCT05701228
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is for adults receiving a kidney, lung, liver, or heart transplant. It will collect blood and tissue samples to learn how the body responds to CMV, a common virus that can cause serious problems after transplant. The goal is to better understand the virus and improve future care. No new treatments are being tested.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CYTOMEGALOVIRUS INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hopitel Pellegrin
Bordeaux, 33076, France
-
Hôpital Edouard Hériot
Lyon, 69003, France
-
Hôpital Foch
Suresnes, 92150, France
-
Hôpital LA PITIE SALPETRIERE
Paris, 75013, France
-
Hôpital Necker
Paris, 75015, France
-
Hôpital Paul Brousse
Villejuif, 94804, France
-
Hôpital Rangueil
Toulouse, 31059, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can immune cells predict herpesvirus danger in transplant patients?
- Can specially grown immune cells from donors beat viruses that won't go away?
- Immune cell levels may predict who will develop severe CMV after transplant
- Lab-Grown immune cells take aim at Life-Threatening viruses in vulnerable patients
- Hidden immune fire: could CMV or autoimmunity be fueling HIV-Related inflammation?
- New study to test antifungal drug safety in organ transplant patients